Clinical Trial of Sarilumab in Adults With COVID-19
Status:
Completed
Trial end date:
2021-04-06
Target enrollment:
Participant gender:
Summary
Early administration of sarilumab in hospitalized patients infected with COVID-19 who have
pulmonary infiltrates and are at high risk of unfavorable evolution could decrease/prevent
progression to acute respiratory distress syndrome (ARDS) requiring high flow nasal
oxygenation (HFNO) or either invasive or non-invasive mechanical ventilation.
Phase:
Phase 2
Details
Lead Sponsor:
Maimónides Biomedical Research Institute of Córdoba
Collaborators:
Consejería de Salud y Familias - Junta de Andalucía Red Andaluza de Ensayos Clínicos en Enfermedades Infecciosas (Red ANCRAID)